HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the...